ATS View
한국어

Samsung Epis Holdings KRX:0126Z0KOSPI

삼성에피스홀딩스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h1
Articles, 7 days10
DART filings, 7 days2
Articles tracked42since Sep 11

In Q2 2026, Samsung Epis Holdings reported revenue of ₩392bn and operating profit of ₩58.7bn. Samsung Epis Holdings (삼성에피스홀딩스) appeared in 10 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Oct 20 with 6 articles. The most common catalyst was contracts & orders (5). It was most often mentioned alongside 글로벌테크놀로지.

Samsung Epis Holdings quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩392bn–₩58.7bn
margin 15.0%		₩85.8bn
Q1 2026₩454bn–₩90.5bn
margin 19.9%		₩99.5bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Samsung Epis Holdings top stories 2 weeks, by number of outlets

  1. 1
    삼성에피스 "희귀질환약 브라질 단독 공급 계약"
    2 outlets · 2 articlesFirst report Oct 20 08:58 뉴시스경제Order / supply contract
  2. 2
    삼성에피스홀딩스 목표가 유지, 마일스톤 서프라이즈-하나
    1 outlets · 1 articlesFirst report Oct 29 07:59 PRESS9Licensing deal
  3. 3
    삼성에피스홀딩스, 마일스톤 효과로 3분기 영업이익 시장 기대 웃돌았다
    1 outlets · 1 articlesFirst report Oct 29 19:39 S저널Licensing deal
  4. 4
    [BioS]삼성에피스, 브라질 '솔리리스 시밀러' 10년 단독공급 계약
    1 outlets · 1 articlesFirst report Oct 20 09:09 이투데이Order / supply contract
  5. 5
    브라질에 희귀질환치료제…삼성에피스 ‘10년 공급 계약’ 따냈다
    1 outlets · 1 articlesFirst report Oct 21 07:00 서울경제Order / supply contract
  6. 6
    삼성에피스 "항암제 후보, FDA 패스트트랙 지정"
    1 outlets · 1 articlesFirst report Oct 21 08:43 뉴시스경제Regulatory approval

Latest Samsung Epis Holdings news Korean headlines